NFL Biosciences launches an offering to raise up to €5.07 million from its shareholders
The offering, proposed on 19 November 2026 to all NFL Biosciences shareholders, represents a potential gross amount of approximately €1.38 million in the first stage. This amount could reach approximately €5.07 million if both categories of warrants are fully exercised.
The Montpellier-based biotech presented this financing as a means of extending its cash runway. It currently estimates this runway to extend to the end of the first half of 2027, including completion of Part A of the TONIC study.
Extending cash runway to negotiate a licence for NFL-101 and NFL-102
According to the company, the potential net proceeds from the warrants should first allow it to extend its cash runway in order to facilitate the conclusion of a licensing agreement covering NFL-101 and NFL-102, “in a strengthened financial position and on the most favourable terms possible”.
According to NFL Biosciences, such an agreement would make it possible to finance the continued clinical development of NFL-101 as well as Part B of the TONIC study. The funds would also be used to start Part B.
They could finally be used to seek, in the first quarter of 2027, the opinion of the FDA and the EMA on the design of the Phase 3 study of NFL-101. This phase incorporates a biomarker identified through post-hoc analyses of the Phase 2 CESTO II study, the predictive character of which will need to be confirmed prospectively.
For NFL-102, the first enrolments in the Phase 2 TONIC study began in November 2026, with 310 participants planned in France. Main results from Part A, covering the first 40 participants, are expected in April 2027.
Bruno Lafont, Chief Executive Officer and co-founder, stated that subscribers “will thus have a period after the publication of the results of the first part of TONIC to decide whether to continue their participation”. He added that management “supports and takes part in this offering”.
Warrants exercisable at €0.30 and then €0.80, with no underwriting guarantee
Each share recorded in the account at the close of trading on 23 November 2026 entitles its holder to one BSA A warrant. Three BSA A warrants entitle the holder to subscribe for one new share at €0.30 from 24 November to 17 December 2026, each new share being accompanied by one BSA B warrant exercisable individually at €0.80 from 4 January to 17 June 2027.
Both categories of warrants must be admitted to trading on Euronext Growth Paris. The issue, decided by the Board of Directors on 6 November 2026, is not subject to any underwriting guarantee: the amount actually raised will depend on the number of warrants exercised.
Based on the 13,832,046 shares outstanding as of 18 November 2026, a shareholder holding 1.00% of the capital who does not subscribe would see their stake reduced to approximately 0.75% after maximum exercise of the BSA A warrants, and then to 0.60% after exercise of the BSA B warrants. Invest Securities acts as placement agent and Uptevia as financial agent.